Kunal Rai։ Koshika Therapeutics Receives CPRIT SEED Award to Advance TIL Therapy Development
Kunal Rai/LinkedIn

Kunal Rai։ Koshika Therapeutics Receives CPRIT SEED Award to Advance TIL Therapy Development

Kunal Rai, Professor and Scientific Director of METI at MD Anderson Cancer Center, shared on LinkedIn:

“I’m thrilled to share that Koshika Therapeutics has received a CPRIT SEED Award for Product Development Research from the Cancer Prevention and Research Institute of Texas.

Cell therapies hold real promise in solid tumors, but infused T cells often lose function.

We see this as an epigenetic problem.

Koshika is building a platform to rewrite the epigenetic programs that govern T cell fitness, and this award will take our lead product, KOS-101, an epigenetically edited TIL therapy, through IND-enabling studies.

Special thanks to the scientists in MD Anderson Epigenomics Therapy Initiative (METI) and my lab Anand Kamal Singh, Suresh Satpati, and Sandeep Kumar Yadav whose work laid the foundation for this work.

I’m grateful to the Office of Technology Commercialization and the IGNITE team at UT MD Anderson, and to Cassian Yee, Jason Bock, Andreas (Andy) Bader, Deepavali Chakravarti, Chantale Bernatchez, Marie-Andrée Forget, Sharmistha Sarkar, Cheryl Beal Anderson, Hristijan (Kiko) Risteski, and many others for their advice and support during the CPRIT application process.

And finally, our experience at Texas Medical Center Innovation Factory Accelerator program (TMCi ACT) contributed significantly to achieve this milestone!

Thank you to CPRIT for investing in Texas biotech and in new ideas for patients with cancer.”

You can also read:

Farhatullah Syed։ Could CAR T Cells Fight Solid Tumors Better by Taking Scheduled Breaks?

Aleix Prat: A Major Step Toward Bringing CAR-T Therapies to Solid Tumors.